Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Sales of AbbVie's Humira are plummeting as the once-top-selling drug fights ...
AbbVie has delivered strong YTD outperformance, with shares up nearly 30% and robust analyst optimism, but I maintain a 'Hold ...
April 26 (Reuters) - AbbVie (ABBV.N), opens new tab expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen after recent changes by U.S. pharmacy benefit managers and as ...
Shares of AbbVie (NYSE:ABBV) were down 6% in afternoon trading Friday in the wake of the drugmaker's Q1 earnings report and news that Cigna (CI) plans to offer a biosimilar of AbbVie’s top-selling ...
AbbVie posted first-quarter results largely as projected, and we don’t expect any major changes to our fair value estimate. With the arrival of the first U.S. biosimilar to Humira, AbbVie’s results ...
AbbVie Inc. raised its profit outlook for this year and next as demand for newer biologic drugs helped fill the gap left by falling Humira sales, but investors were disappointed as Botox sales missed ...
(Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira. The ...
NEW YORK, Jan 27 (Reuters) - Abbott Laboratories reported stronger-than-expected fourth-quarter results, helped by lower taxes and reduced expenses, but weak U.S. sales of its Humira arthritis drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback